✦ LIBER ✦

P.4.006 Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease

✍ Scribed by H.-J. Moebius; B. Reisberg; F. Schmitt; R. Doody

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.5.a.006 Long-term safety and tolerabil

✍ S. Bakchine; M. Rainer 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

A long-term, open-label extension study

✍ Perhach, James; Graham, Stephen 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 54 KB

A 24-week, open-label extension to the A

✍ Farlow, Martin; Grossberg, George; Sadowsky, Carl; Meng, Xiangyi; Somogyi, Moniq 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 51 KB